Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 2/20 | 0.54 |
| ▸ | CA12 | O43570 | 3/20 | 0.53 |
| ▸ | CA1 | P00915 | 3/20 | 0.53 |
| ▸ | CA2 | P00918 | 3/20 | 0.53 |
| ▸ | CA7 | P43166 | 3/20 | 0.53 |
| ▸ | CA9 | Q16790 | 3/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.46 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | ELANE | P08246 | 2/20 | 0.44 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2932838 | 0.89 | BCL2L1 (0.53) | PTPN11CA12CA1CA2CA7 | |
| SCHEMBL2176596 | 0.84 | LCK (0.55) | PTPN11CA12CA1CA2CA7 | |
| SCHEMBL2390984 | 0.83 | HSD17B2 (0.52) | PTPN11CA12CA1CA2CA7 | |
| SCHEMBL30260014 | 0.83 | PTPN11 (0.54) | PTPN11CA12CA1CA2CA7 | |
| SCHEMBL2390084 | 0.81 | ALDH1A1 (0.46) | PTPN11CA12CA1CA2CA7 | |
| SCHEMBL163865 | 0.81 | CA12 (0.57) | PTPN11CA12CA1CA2CA7 | |
| SCHEMBL4079402 | 0.80 | CA12 (0.56) | PTPN11CA12CA1CA2CA7 | |
| Acetic Acid SCHEMBL11123129 | 0.80 | LMNA (0.51) | PTPN11CA12CA1CA2CA7 | |
| SCHEMBL8347077 | 0.79 | SMN1; SMN2 (0.55) | CA12CA1CA2CA7CA9 | |
| SCHEMBL11124330 | 0.79 | NPC1 (0.53) | PTPN11CA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160244460-A1 | ANTIVIRAL COMPOUNDS | Janssen Pharmaceuticals, Inc. | 2016-08-25 | — | — | US | disclosed |
| US-20160244460-A1 | ANTIVIRAL COMPOUNDS | Janssen Pharmaceuticals, Inc. | 2016-08-25 | — | — | US | disclosed |
| US-RE42700-E1 | Induction of apoptosis in cancer cells | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2011-09-13 | — | — | US | disclosed |
| US-7053071-B2 | For therapy of leukemia or other forms of cancer or for treating disease conditions caused by apoptosis of cells | THE BURNHAM INSTITUTE (US) | 2006-05-30 | — | — | US | disclosed |
| EP-1456165-A1 | INDUCTION OF APOPTOSIS IN CANCER CELLS | The Burnham Institute (US) | 2004-09-15 | — | — | EP | disclosed |
| US-20030176506-A1 | Induction of apoptosis in cancer cells | BURNHAM INSTITUTE FOR MEDICAL RESEARCH | 2003-09-18 | — | — | US | disclosed |
| WO-2003048101-A1 | INDUCTION OF APOPTOSIS IN CANCER CELLS | THE BURNHAM INSTITUTE (US) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244460-A1 | ANTIVIRAL COMPOUNDS | MAVS, SARS1, ZC3HAV1 | PTPN11 2423/4885CA12 4108/4885CA1 4791/4885 |
| US-20030176506-A1 | Induction of apoptosis in cancer cells | MCL1, BAD, BCL2 | PTPN11 2842/4885CA12 2413/4885CA1 1420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.